- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Paul M. Barr, MD | Authors
Paul M. Barr, MD, Examines Head-to-Head Data on BTK Inhibitors in Previously Treated, High-Risk CLL
June 09, 2021
CancerNetwork® sat down with Paul M. Barr, MD, at the 2021 ASCO Annual Meeting to talk about what data has the greatest potential to impact standard treatment of chronic lymphocytic leukemia.
Paul M. Barr, MD, Discussed 7-Year Follow-Up Data for Ibrutinib as Frontline Treatment of CLL
June 04, 2021
CancerNetwork® sat down with Paul M. Barr, MD, at the 2021 ASCO Annual Meeting to talk about data from RESONATE-2 showing sustained progression-free and overall survival in patients with chronic lymphocytic leukemia being treated with ibrutinib in the frontline setting.
COUNTERPOINT: Can Chemotherapy Be Eliminated in the Treatment of Follicular Lymphoma?
August 15, 2018
It is clear that chemoimmunotherapy has redefined the history of follicular lymphoma, producing survival rates measured in decades.
Diffuse Large B-Cell Lymphoma in the Very Elderly: The Case for Refining Our Clinical Trials
February 16, 2013
Further prospective clinical trials in very elderly patients with DLBCL are clearly needed. Complementing the growing need for such trials, an evolving clinical trial infrastructure, geriatric oncology support, and novel therapeutics are making such studies feasible in the current era.